Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease

Springer Science and Business Media LLC - Tập 11 Số 1 - 2021
Manal Sabry Mohamed1, Tarek Youssef1, Esraa Ebrahim Abdullah1, Ahmed Elmetwally Ahmed1
1Gastroenterology, Hepatology and Internal Medicine Department, Ain Shams University, Cairo, Egypt

Tóm tắt

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases, particularly in Egypt. It is defined as the accumulation of lipids inside the hepatocytes, in the absence of other etiologies of hepatic damage. It is frequently associated with obesity, diabetes mellitus, and metabolic syndrome. Adiponectin is an abundant adipocyte-derived protein with well-established anti-atherogenic, insulin-sensitizing, and anti-inflammatory properties. The liver is a major target organ for adiponectin especially in fatty liver diseases, and this adipocytokine has the ability to control many liver functions including metabolism, inflammation, and fibrosis. In this study, we aimed to find out the correlation between the degree of liver fibrosis in NAFLD patients and their serum adiponectin level as a future non-invasive method for the assessment of liver fibrosis to substitute liver biopsy to avoid its hazardous complication and also to study the correlation between diabetes mellitus as well as obesity and serum adiponectin level. Results Fifty patients were selected to participate in our study based on our inclusion criteria. They were recruited from the Internal Medicine Department, Gastroenterology Clinic in Al-Demerdash Hospital using a convenient sampling method. Diagnosis of NAFLD was confirmed by laboratory markers: aspartate aminotransferase (AST), alanine aminotransferase (ALT), lipid profile, ultrasound, and FibroScan examination. Analyzing the adiponectin levels showed that besides its significant correlation with body mass index (BMI), hypertension, diabetes mellitus, and dyslipidemia, it was significantly lower in the high-grade fibrosis group compared to the low-grade fibrosis group with a P-value of (0.000) and a cutoff value for stage 3/4 fibrosis of about 2.31 μg/ml which marked a promising hope of adiponectin being of protective value against liver fibrosis. Conclusion Both serum levels and hepatic adiponectin receptor expression are decreased in NAFLD. Therefore, either adiponectin itself or adiponectin-inducing agents might be of key therapeutic interest in the near future in the treatment of NAFLD.

Từ khóa


Tài liệu tham khảo

Baden MY, Yamada Y, Takahi Y et al (2013) Association of adiponectin with blood pressure in healthy people. Clin Endocrinol 78(2):226–231

Bae JC, Cho NH, Kim JH et al (2020) Association of body mass index with the risk of incident type 2 diabetes, cardiovascular disease, and all-cause mortality: a community-based prospective study. Endocrinol Metab 35(2):416–424

Bhowmik B, Siddiquee T, Mujumder A et al (2018) Serum lipid profile and its association with diabetes and prediabetes in a rural Bangladeshi population. Int J Environ Res Public Health 15(9):1944

Brzeska A, Sołtysiak M, Ziemak J et al (2018) Plasma adiponectin in hypertensive patients with and without metabolic syndrome. Arterial Hypertension 22(1):29–36

Buch A, Kaur S, Nair R et al (2017) Platelet volume indices as predictive biomarkers for diabetic complications in type 2 diabetic patients. J Lab Phys 9(2):84–88

Burhans MS, Hagman DK, Kuzma JN et al (2011) Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol 9(1):1–58

Caballería L, Pera G, Arteaga I et al (2018) High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol 16(7):1138–1145

Cao W, Zhao C, Shen C et al (2013) Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS ONE 8(12):e82092

Coban E, Ozdogan M, Yazicioglu G et al (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59:981–982

Davis SK, Gebreab SY, Xu R et al (2015) Association of adiponectin with type 2 diabetes and hypertension in African American men and women: the Jackson Heart Study. BMC Cardiovasc Disord 15(1):13

Di Ciaula A, Baj J, Garruti G et al (2020) Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk. J Clin Med 9(8):2648

Hekimsoy Z, Payzin B, Ornek T et al (2004) Mean platelet volume in type 2 diabetic patients. J Diabetes Complications 18:173–176

Hertelyova Z, Salaj R, Chmelarova A et al (2016) The association between lipid parameters and obesity in university students. J Endocrinol Invest 39:769–778

Izadi V, Farabad E, Azadbakht L (2013) Epidemiologic evidence on serum adiponectin level and lipid profile. Int J Prev Med 4(2):133

Jaafar RF, Ali AM, Zaghal AM et al (2019) Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 31(12):1540–1544

Jamshidi L and Seif A (2017): Association between obesity, white blood cell and platelet count. Zahedan J Res Med Sci. 19: e4955.

Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15(4):6184–6223

Kolhar U, Priyanka P (2017) Study of serum lipid profile in type 2 diabetes mellitus patients and its association with diabetic nephropathy. Int J Adv Med 4(6):1513–1516

Kshirsagar RM, Deoke S, Akhtar S (2019) Platelet indices in type 2 diabetes mellitus and their association with microvascular complications. Panacea J Med Sci 9(1):23–28

Kumar R, Rastogi A, Sharma MK et al (2013) Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 58(1):265–274

Liu F, Zhou H, Cao L et al (2018) Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study. Lipids Health Dis 17(1):221

Lucero D, Miksztowicz V, Gualano G et al (2017) Nonalcoholic fatty liver disease associated with metabolic syndrome: influence of liver fibrosis stages on characteristics of very low-density lipoproteins. Clin Chim Acta 473:1–8

Maghsoudi Z, Kelishadi R, Hosseinzadeh-Attar MJ (2016) The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents. Diabetes Metab Syndr 10(2):S43–S46

Marchisello S, Di Pino A, Scicali R et al (2019) Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview. Int J Mol Sci 20(8):1948

Nazal L, Riquelme A, Solís N et al (2010) Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg 20(10):1400–1407

Ratziu V, Giral P, Charlotte F et al (2000) Liver fibrosis in overweight patients. Gastroenterology 118(6):1117–1123

Riaz H, Khan MS, Siddiqi TJ et al (2018) Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of Mendelian randomization studies. JAMA Netw Open 1(7):e183788

Rojas E, Rodríguez-Molina D, Bolli P et al (2014) The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 16(8):463

Satapathy SK, Sanyal AJ (2015) Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35:221–235

Stern JH, Rutkowski JM, Scherer PE (2016) Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 23(5):770–784

Sumida Y, Yoneda M (2018) Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53:362–376

Udomsinprasert W, Honsawek S, Poovorawan Y (2018) Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol 10(10):708

Yosaee S, Khodadost M, Esteghamati A et al (2019) Adiponectin: an indicator for metabolic syndrome. Iran J Public Health 48(6):1106–1115

Zhang H, Niu Y, Gu H et al (2019) Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease. J Clin Lab Anal 33(3):e22709

Zhao L, Fu Z, Liu Z (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends Cardiovasc Med 24(8):319–324

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 11 Số 1

Thông tin tác giả